754 Phase 1 trial of LYL797, a ROR1-targeted CAR T-cell therapy enhanced with genetic and epigenetic reprogramming, in advanced triple-negative breast cancer (TNBC) and non-small cell lung cancer (NSCLC)
Regular and Young Investigator Award Abstracts | October 31, 2023 | Volume: No volume available | Issue: No issue available | Pages: A850-A850
10.1136/jitc-2023-sitc2023.0754